This collection of drawings offers a visual exploration of compassion, respect, and dignity in clinical relationships and encounters.

In 1984, Hatch-Waxman tried to balance drug innovation against availability; it was tested in the US Supreme Court in 2013.

This mixed media collage explores pharmaceutical companies’ influence on the daily lives of American citizens and on patient-physician relationships.

Louisiana has a subscription model for hepatitis C treatment, but costly medications challenge states’ capacities to cover patients.

The AMA Code of Medical Ethics offers guidance on stewardship and professionalism.

This graphic narrative considers the shortage of normal saline in US health care organizations after Hurricane Maria devastated Puerto Rico in 2017.

Since the 1960s, drug names have been products of complex, multiparty negotiations in which interests of patients, pharmaceutical firms, clinicians, and US and international regulators must be balanced.

Overall utilization of the few biosimilars currently available to patients has been limited.

Closed formularies can be justified when they enable spending on other socially valuable aims, but they can single out poor patients.

Safeguards are urgently needed for assessments of what constitutes appropriate care for unaccompanied minors in US detention facilities.